REG - Ergomed plc - Investor Meeting <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

04/07/2017 12:30

RNS Number : 0817K
Ergomed plc
04 July 2017
PRESS RELEASE
FOR IMMEDIATE RELEASE
Investor meeting 
London, UK - 4 July 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is today hosting an investor meeting at its headquarters in Guildford, UK.
No inside information will be disclosed. The presentation is available on the Group's website.
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Dan Weng (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer)



Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)



N+1 Singer
Tel: +44 (0) 20 7496 3000
Alex Price (Joint Broker)



Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott / Ivar Milligan
ergomed@consilium-comms.com


MC-Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke

About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries. 
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed acquired a pipeline of proprietary development products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCZMGGNMDGGNZM